Related references
Note: Only part of the references are listed.Application of molecular imaging technology in tumor immunotherapy
Yiming Meng et al.
CELLULAR IMMUNOLOGY (2020)
Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody
Camilla Christensen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
Yue Song et al.
IMMUNOTHERAPY (2019)
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations
Barbora Brodska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Daniele Cretella et al.
CANCERS (2019)
Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
Peter Wierstra et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY (2019)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Paulino Tallon de lara et al.
CLINICAL CANCER RESEARCH (2018)
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
Toshifumi Doi et al.
ONCOLOGY REPORTS (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Considerations in producing preferentially reduced half-antibody fragments
Asta Makaraviciute et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Chunxiao Xu et al.
CANCER CELL (2014)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Alison M. Paterson et al.
JOURNAL OF IMMUNOLOGY (2011)
Site-specifically Zr-89-labeled monoclonal antibodies for ImmunoPET
Jeff N. Tinianow et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Activation of Akt as a Mechanism for Tumor Immune Evasion
Kyung Hee Noh et al.
MOLECULAR THERAPY (2009)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Gemcitabine as significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects
Eiji Suzuki et al.
CANCER BIOLOGY & THERAPY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Share Paper
